Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Badarch, Bat-Ireedui

Loading...
Thumbnail Image
Товч нэр
Badarch, Bat-Ireedui
Бүтэн нэр
Badarch Bat-Ireedui
Латин нэр
Badarch Bat-Ireedui
Албан тушаал
Судлаач
Харьяалал

Settings

Now showing 1 - 10 of 16
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Renal Dysfunction After Liver Transplantation: a Single Center Study
    (Mongolian National University of Medical Sciences, 2021-12-31)
    Batsaikhan Batsuuri
    ;
    Fidel López‐Verdugo
    ;
    Bat-Ireedui Badarch
    ;
    Suvd Nergui
    ;
    Ariunaa Togtokh
    Objectives: Mongolia is known as one of the countries with a high prevalence of viral hepatitis infection and its related liver cirrhosis and HCC. Therefor, liver transplantation (LT) surgery increases from year to year in Mongolia. Our goal was to evaluate post-transplant renal dysfunction (PTRD) and to investigate the predicting factors for renal dysfunction after LT. Methods: The impact of graft ischemic time, peri- and postoperative blood product transfusion, perioperative hemodynamics, time to extubating, intensive care length of stay, incidence of chronic renal failure, and mortality and morbidity were examined alone and then as a combined outcome. Results: Early renal dysfunction was identified by measuring serum creatinine and glomerular filtration rate. In our investigation which was a study group of patients following liver transplantation (LT), the following renal dysfunctions were found: 39% of recipients in the study had renal dysfunction, while the rest had no renal dysfunction. The average creatinine level of the recipients who had a renal dysfunction after LT, was 0.825 ± 0.24 mg/dl and the glomerular filtration rate was 111 ± 36.3 ml/min, and statistically significant. Conclusion: Preoperative kidney function plays a crucial role for postoperative renal dysfunction.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Hepatic arterial reconstruction using saphenous vein graft interposition for living donor liver transplantation
    (2023-06-08)
    Batsaikhan Bat‐Erdene
    ;
    Bat-Ireedui Badarch
    ;
    Sergelen Orgoi
    ;
    Erdene Sandag
    ;
    Batsaikhan Batsuuri
    Batsaikhan BAT-ERDENE*, Bat-Ireedui BADARCH, Sergelen ORGOI, Erdene SANDAG, Batsaikhan BATSUURI, Urnult GANBOLD, Otgonbayar SETEVDORJ. Ann Hepatobiliary Pancreat Surg 2023;27:S313. https://doi.org/10.14701/ahbps.2023S1.EP-46
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Massive gastrointestinal bleeding following living donor liver transplantation: a case report
    (The Korean Society for Transplantation, 2022-11-17)
    Ganbaatar, Bayarbileg
    ;
    Badarch, Bat-Ireedui
    ;
    Batsuuri, Batsaikhan
    ;
    Orgoi, Sergelen
    ;
    Sainbyan, Tamir
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    BUILDING A SELF-SUFFICIENT LIVER TRANSPLANT PROGRAM IN MONGOLIA
    (Ovid Technologies (Wolters Kluwer Health), 2020-09)
    Banzragch, Ganzorig
    ;
    Batsuuri, Batsaikhan
    ;
    Badarch, Bat-Ireedui
    ;
    Sainbuyan, Tamir
    ;
    Erdene, Sarnai
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Living donor liver transplantation postoperative donor follow-up
    (2022-11-14)
    Bat-Ireedui Badarch
    ;
    Munkhbold Tuul
    ;
    Bayarbileg Ganbaatar
    ;
    Tamir Sainbuyan
    Background: Mongolia has the highest prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus infection. The prevalence of HCV was 18.9%. Additionally, HBV infection was observed in 23.1% and 1.2% were coinfected with HCV and HBV in Mongolia. Mongolia has the highest HCC incidence in the world (78.1/100,000, 3.5* higher than China). Methods: Of the 156 intended living donors, who had applied for liver donation, living donor liver transplantation (LDLT) surgery was performed at First Central Hospital of Mongolia from September, 2011 to September, 2020. All donors were healthy adults and kin to the recipients. The in-hospital and follow-up data was acquired from the patient records and the Organ Transplantation Center of First Central Hospital of Mongolia. The living donor morbidity was graded according to the modified Clavien-Dindo classification system. Results: Therefore, LDLT was performed 156 donors, 91 male donors (57.9%). The median age of the donors was 32.79.03 years (range, 18-49 years). Most donors (151, 96.7%) donated the right lobe liver. The remnant volume of the right lobe of the liver donor is 713.7152.4 g (59.42%), the remnant volume of the remaining liver is 487 g (40.58%). The average duration of LDLT is 6 hours 38 minutes2 hours 2 minutes, and the intensive care bed is 5.42.4 days. Total bilirubin (1.18 mg/dL), alanine aminotransferase (ALT; 204.9 U/L), aspartate aminotransferase (AST; 224.07 U/L) increased from the first postoperative day of LDLT surgery in all donors, on the seventh day after surgery total bilirubin (0.82 mg/dL), ALT (50.84 U/L), AST (72.69 U/L) decreased too normal. All the donors have led a normal life after donation postoperation seventh-tenth day. Only one case had a complication Clavien-Dindo Classification Grade3b, which is portal vein stenosis. Totally five deliveries had during these 10 years. There was no postoperative mortality. Conclusions: As far the liver donor survival rate after liver transplantation in our hospital is 100% since the first transplantation. Living donor liver transplantation is relatively safe for donors and severe postoperation complication is rare.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Impact factors leading to renal impairment after liver transplant surgery: a single center study
    (2022-11-14)
    Batsaikhan Batsuuri
    ;
    Shiirevnyamba Avirmed
    ;
    Bat-Ireedui Badarch
    ;
    Fidel López‐Verdugo
    ;
    Ariunaa Togtokh
    Batsaikhan Batsuuri, Shiirevnyam Avirmed, Bat-Ireedui Badarch, Fidel Lopez-Verdugo, Ariunaa Togtokh, Shiirevnyam Avirmed, Sergelen Orgoi. Korean J Transplant 2022;36:195. https://doi.org/10.4285/ATW2022.F-3297
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    P.389: No difference in recurrent hepatocellular carcinoma rates in liver transplanted patients receiving mTOR inhibitors compared to non-mTOR group.
    (Wolters Kluwer, 2024-09-01)
    Anar Ganbold
    ;
    Margad-Erdene Erdenechuluun
    ;
    Bayarmaa Ochirkhuree
    ;
    Urnultsaikhan Ganbold
    ;
    Ulzii-Orshikh Namkhai
    Introduction: A liver transplantation (LT) is a first line therapeutic choice for patients with hepatocellular carcinoma (HCC). Mammalian Target of Rapamycin (mTOR) inhibitors act as immunosuppressant and indicated against HCC recurrence in LT patients. The efficacy of mTOR inhibitors in preventing HCC recurrence remains contentious. Methods: We retrospectively enrolled 45 patients (average age 50, M/F:29/16) who had a history of HCC at the time of LT operation at a single center (2011-2023) and divided into a mTOR and non-mTOR groups. Initial Alfa-fetoprotein (AFP), Protein induced by vitamin K absence-II (PIVKA-II) levels, contrast-enhanced abdominal computer-assisted tomography (CT) scans were compared to most recent results, explant histology was also assessed for HCC extent. Decision to transplant was made based on Milan criteria. Student t-test was used to determine statistical significance (p<0.05). Results: In the mTOR group (n=23, average age 52.7) there were 2 confirmed HCC recurrences with elevated markers and positive CT scans. In the non-mTOR group (n=22, average age 47.4) there was 1 confirmed case of HCC. A recurrence rate of 6.67% was recorded overall, 8.7% and 4.55% for mTOR and non-mTOR (p=0.28), respectively. All three recurrences were detected within 24 months of the operation. For recurrent HCCs, the average levels of PIVKA-II and AFP were 27010mAU/ml and 2842.7ng/ml, respectively. There was no difference in number and mode of pre-LT bridging therapies (TACE or RFA) with regards to recurrence. There were two cases of elevated PIVKA-II without a radiologic confirmation. Conclusion: Adherence to the Milan criteria and application of pre-LT bridging therapies will keep the recurrence rate below 10%. Any possible recurrence will be diagnosed within 24 months of LT. Administration of mTOR inhibitors can be stopped after 2 years as part of the physician-guided minimization of immune suppression regimen.